Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-tha...

Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, mark...

Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfoli...

Biocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous s...

Novartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...

Bayer, through its subsidiary Viralgen, is advancing cell and gene therapies (CGT) to cure diseases like Parkinson's, oncology, cardiovascu...

AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the...

AstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India...

Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt,...

AstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...

Zydus Lifesciences is exploring mergers, acquisitions, and licensing to bolster its specialty portfolio in the US, particularly for the pot...

The facility currently occupies 334,000 square feet of office space at Ramanujan IT City, with plans to add approximately 180,000 square fe...

AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...

Before joining Zydus, he was the President of Red Oak Sourcing, leading the company's "multibillion-dollar generic portfolio", overseeing a...

Under the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and com...

Sanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...

A day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...